Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory targetSNP detection in mRNA in living cells using allele specific FRET probesGenetic perturbation of the putative cytoplasmic membrane-proximal salt bridge aberrantly activates alpha(4) integrinsRNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT miceHyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response.Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles.Detection of intestinal inflammation by MicroPET imaging using a (64)Cu-labeled anti-beta(7) integrin antibody.RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphomaAL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes.The human P-glycoprotein transporter enhances the type I interferon response to Listeria monocytogenes infectionSelective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1.Nanodiamonds of Laser Synthesis for Biomedical Applications.Cell-specific uptake of mantle cell lymphoma-derived exosomes by malignant and non-malignant B-lymphocytes.Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.RNAi nanomedicines: challenges and opportunities within the immune system.Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: a mini-review.Special delivery: targeted therapy with small RNAs.Reshaping the future of nanopharmaceuticals: ad iudicium.Polysaccharides as building blocks for nanotherapeutics.Altering the immune response with lipid-based nanoparticles.A daunting task: manipulating leukocyte function with RNAi.Featuring the special issue guest editor: Dan Peer, Ph.D.Precision medicine--delivering the goods?Overcoming multidrug resistance with nanomedicines.Modulation of Immune Response Using Engineered Nanoparticle Surfaces.Nanomedicine as an emerging platform for metastatic lung cancer therapy.Transforming Nanomedicines From Lab Scale Production to Novel Clinical Modality.RNA nanomedicines: the next generation drugs?Harnessing nanomedicine for therapeutic intervention in glioblastoma.Zooming in on selectins in cancer.Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines.Quaternized starch-based carrier for siRNA delivery: from cellular uptake to gene silencing.Triggered-release polymeric conjugate micelles for on-demand intracellular drug delivery.Next-Generation Lipids in RNA Interference Therapeutics.Integrin-targeted nanoparticles for siRNA delivery.Targeting anthracycline-resistant tumor cells with synthetic aloe-emodin glycosidesEnhanced bioavailability of polyaromatic hydrocarbons in the form of mucin complexes.IKAP/hELP1 down-regulation in neuroblastoma cells causes enhanced cell adhesion mediated by contactin overexpression.Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors.Colitis ImmunoPET: Defining Target Cell Populations and Optimizing Pharmacokinetics.
P50
Q28266775-90758DA3-483D-4067-9847-4B20F57449A7Q28536974-E33D0C1C-DA44-4985-9490-85E44BEF1EA8Q30484970-AB789072-12B3-4C00-80E8-F478A1455F40Q33730699-4A3203E7-A1E4-41A1-A843-5D01C0BB77B3Q33957396-9039A20C-0D8A-43F5-9713-D5946E0905C3Q34042942-D108F383-AC95-4415-A969-0CA73A5962A6Q34091752-ECAC823C-6F51-4046-A563-DB120CCC0621Q34385029-F2F4B843-AAE3-477B-AC11-C1ACCEA13A25Q35080405-F615470C-7CEE-4EF5-9794-9BF18D7E8E01Q35609414-9DFB4AA6-D1C2-40B6-B93A-F68F9AD57B8BQ35676793-6672C230-1992-466E-A088-04E6DDEB8CE5Q35768374-6291093F-7BB5-4D40-BC7F-0A99EDC2CAB8Q35812755-252F6683-7904-450D-8C22-47DA5B417E31Q35812755-FC789313-8E70-40BB-B0FD-2C70069EAE7DQ36459323-B781D0BB-B381-44E1-852B-0B6FEB205D87Q37750214-DE33F9F8-2AAF-4758-B4C6-9872F835A334Q37771980-C230794D-5B3B-436D-8141-725C932BB4F3Q37864924-F54FADB3-B245-4039-B4F9-84703441DAAEQ37944864-62E58633-50C3-4418-9921-C7D7902BA4B2Q37956480-2A9AA551-868D-4B3D-9902-FC627155E783Q37974348-37B4509A-3948-48E2-8FF8-22AA987F4E57Q38095502-EDA7AE2F-F49F-43FC-BD35-9A80B2C91D12Q38200370-2B6BF234-BE96-48FD-A493-A528E7AF05E1Q38207405-DE3CF00A-A10E-4E2E-8005-2297C120BE40Q38249954-0580FC2B-BAB3-4FCA-ADB1-C69A623D5387Q38350859-F96BB2DA-F8E2-49A0-8142-056017A5C6A9Q38463092-324222FD-AA64-4FE7-98A3-76A85B828684Q38687936-59DBD997-2CFF-41B9-8BC8-FAC4E981A963Q38698453-4E7ED8AB-4D4F-431B-B326-ADFA0E1826E2Q38862946-EFBF8E8F-8E7E-4652-A6A4-9A605FB50038Q38881362-727F1571-4EEC-4BB5-9249-EDEF6231A675Q38918775-527222F2-6F6A-47FC-A408-8DC2B3844571Q38998692-AC4C7525-A446-47AF-80E8-3E4FFBA4367AQ39036038-E4D978F3-03B4-4016-9F15-D2E623946193Q39447627-E5DDD38A-82DC-469D-BEBD-003F384B20A9Q39475698-92F7126D-2A8C-46C5-B886-2902A968E70BQ39510887-D26648DE-915D-4B83-B2FE-758512E83630Q39589883-1499B0A4-452C-430C-B0D0-A9FD413B496AQ39673684-D8C3AA6C-021D-4B83-884F-22DC972C519EQ39682110-19FB95B9-5D3B-48C4-91C2-58A867BE28FB
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Dan Peer
@ast
Dan Peer
@de
Dan Peer
@en
Dan Peer
@es
Dan Peer
@fr
Dan Peer
@it
Dan Peer
@nl
Dan Peer
@sl
type
label
Dan Peer
@ast
Dan Peer
@de
Dan Peer
@en
Dan Peer
@es
Dan Peer
@fr
Dan Peer
@it
Dan Peer
@nl
Dan Peer
@sl
prefLabel
Dan Peer
@ast
Dan Peer
@de
Dan Peer
@en
Dan Peer
@es
Dan Peer
@fr
Dan Peer
@it
Dan Peer
@nl
Dan Peer
@sl
P1053
A-1785-2011
P106
P1153
13610740700
P1960
XaWep9sAAAAJ
P21
P31
P3829
P496
0000-0001-8238-0673
0000-0003-4408-8350